Neurocrine Biosciences Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Neurocrine Biosciences stock.
View analyst ratings for Neurocrine Biosciences or view top-rated stocks.

Wall Street analysts have given Neurocrine Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Neurocrine Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Neurocrine Biosciences saw a drop in short interest in the month of August. As of August 13th, there was short interest totaling 3,570,000 shares, a drop of 13.6% from the July 29th total of 4,130,000 shares. Based on an average daily volume of 738,600 shares, the days-to-cover ratio is currently 4.8 days. Currently, 3.9% of the shares of the company are short sold.
View Neurocrine Biosciences' Short Interest.

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Neurocrine Biosciences.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings data on Monday, August, 2nd. The company reported $0.43 earnings per share for the quarter, missing analysts' consensus estimates of $0.52 by $0.09. The firm had revenue of $288.90 million for the quarter, compared to the consensus estimate of $274.47 million. Neurocrine Biosciences had a net margin of 35.34% and a trailing twelve-month return on equity of 33.04%.
View Neurocrine Biosciences' earnings history.

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NBIX stock has increased by 11.4% and is now trading at $95.72.
View which stocks have been most impacted by COVID-19.

15 brokers have issued 1-year price objectives for Neurocrine Biosciences' stock. Their forecasts range from $90.00 to $163.00. On average, they expect Neurocrine Biosciences' stock price to reach $119.31 in the next twelve months. This suggests a possible upside of 24.6% from the stock's current price.
View analysts' price targets for Neurocrine Biosciences or view top-rated stocks among Wall Street analysts.

11 employees have rated Neurocrine Biosciences CEO Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among Neurocrine Biosciences' employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Novavax (NVAX), Incyte (INCY), Repligen (RGEN), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of NBIX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), The Walt Disney (DIS), Tesla (TSLA), Square (SQ) and salesforce.com (CRM).

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.50%), Price T Rowe Associates Inc. MD (5.32%), Jefferies Group LLC (0.00%), Bellevue Group AG (3.19%), Bank of New York Mellon Corp (2.13%) and DSM Capital Partners LLC (1.62%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy and Stephen A Sherwin.
View institutional ownership trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Capital International Investors, Bank of New York Mellon Corp, Bellevue Group AG, Renaissance Technologies LLC, Bank of America Corp DE, Bank of America Corp DE, and Perceptive Advisors LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Eiry Roberts, Eric Benevich, Gary A Lyons, Julie Cooke, Kevin Charles Gorman, Malcolm Lloyd-Smith, and Matt Abernethy.
View insider buying and selling activity for Neurocrine Biosciences or view top insider-selling stocks.

NBIX stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Woodline Partners LP, DSM Capital Partners LLC, Vanguard Group Inc., Amundi, Allianz Asset Management GmbH, Westfield Capital Management Co. LP, and State of Wisconsin Investment Board.
View insider buying and selling activity for Neurocrine Biosciences or or view top insider-buying stocks.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NBIX stock can currently be purchased for approximately $95.72.

Neurocrine Biosciences has a market capitalization of $9.05 billion and generates $1.05 billion in revenue each year. The company earns $407.30 million in net income (profit) each year or $4.16 on an earnings per share basis.

Neurocrine Biosciences employs 845 workers across the globe.

The official website for Neurocrine Biosciences is www.neurocrine.com.

Neurocrine Biosciences is headquartered at 12780 EL CAMINO REAL, SAN DIEGO CA, 92130.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 617-7600 or via email at [email protected]